Organization & Developments: Sutro

Parents

Sutro Biopharma, Inc. (NASDAQ: STRO)*

Children

*Developing protein-based therapeutics and vaccines using cell-free protein synthesis technology.
*Investors’ bet they can create genetically engineered protein drugs with greater capability to bind with targets than today’s antibodies
*Per the company, cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics.
*Quite a few companies have been sprouting up and raising cash in the last couple years with similar notions of developing “bio-superiors” or “bio-betters.” (2010)
2021: Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data
2022: Sutro Biopharma (STRO) Investor Presentation - Slideshow_ seekingalpha.com
2023: Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching
2024: Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
2024: Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC
2024: Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer
2024: Sutro Biopharma Highlights Next-Generation ADC Innovation
2024: Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable?
2024: Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology_ seekingalpha.com
2025: Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless_seekingalpha.com
2025: Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review
2025: Sutro discards CEO, 50% of staff and lead ADC to save cash

Jumps

*Key People: Sutro
Finance & Acquisitions: Sutro

Made with TheBrain